Compare WD 40 Company (WDFC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
WD 40 Company vs State Street SPDR S&P Biotech ETF — how do they compare? WD 40 Company trades at $231.66 (market cap $3.13B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: WD 40 Company pays a 1.75% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, WD 40 Company nearer its low. Which is the better fit depends on your goals.
| WDFC | XBI | |
|---|---|---|
Market Cap | $3.13B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $264.91 | $164.28 |
52-Week Low | $187.52 | $86.92 |
Enterprise Value | $3.18B | — |
Dividend Yield | 1.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
WDFC trades at $232.50, down 0.86% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $2.33 per share, beating estimates, but faces gross margin pressure from input costs. Revenue is projected to grow to $675 million in 2026, though net income may dip slightly. A dividend of $1.02 per share is payable July 31, 2026.
Outlook is mixed: solid brand strength and cash flow support stability, but high valuation ratios and margin pressures pose risks. Analyst consensus is cautious with 71% hold ratings. Key catalysts include execution against growth strategy, while headwinds include cost inflation and competitive challenges.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
